Eli Lilly (LLY.N)has retracted a request for European Union approval of its antibody-based treatment for COVID-19, citing a lack of demand from EU member states as the bloc focuses on other suppliers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,